Qualigen Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
FFR$0.91+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
| Convertible · Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity (Deficit) | |
| Balance at December 31, 2024 | 6,256 | $5,716,400 | 736,431 | $65,314 | $119,958,897 | $(123,061,575) | $2,679,036 |
| Issuance of common stock for the conversion of Series A-2 preferred shares | (3,235) | (2,893,306) | 888,879 | 889 | 2,892,417 | — | — |
| Stock-based compensation | — | — | — | — | 269 | — | 269 |
| Net loss | — | — | - | — | — | (2,646,172) | (2,646,172) |
| Balance at March 31, 2025 | 3,021 | 2,823,094 | 1,625,310 | 66,203 | 122,851,583 | (125,707,745) | 33,134 |
| Issuance of common stock for the conversion of Series A-2 preferred shares | (37) | (33,087) | 10,165 | 10 | 33,076 | — | — |
| Net loss | — | — | - | — | — | (1,685,417) | (1,685,417) |
| Balance at June 30, 2025 | 2,984 | $2,790,007 | 1,635,475 | $66,213 | $122,884,659 | $(127,393,162) | $(1,652,283) |
| Convertible · Additional · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Paid-In · Accumulated · Stockholders’ | ||||||||
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity (Deficit) | ||||||||
| Balance at December 31, 2023 | - | $— | 107,243 | $43,262 | $114,655,565 | $(116,802,384) | $(2,103,557) | |
| Monthly redemptions of convertible debt into common stock | — | — | 22,771 | 1,138 | 545,094 | — | 546,232 | |
| Fair value of warrant modification for professional services | — | — | — | — | 9,737 | — | 9,737 | |
| Stock-based compensation | — | — | — | — | 58,651 | — | 58,651 | |
| Net loss | — | — | — | — | — | (2,032,751) | (2,032,751) | |
| Balance at March 31, 2024 | — | — | 130,014 | 44,400 | 115,269,047 | (118,835,135) | (3,521,688) | |
| Voluntary conversion of convertible debt into common stock | 28,000 | $1,400 | $278,801 | 280,201 | ||||
| Monthly redemptions of convertible debt into common stock | — | — | 22,726 | 1,137 | 355,959 | — | 357,096 | |
| Stock issued upon partial exercise of warrants | — | — | 11,538 | 577 | 149,423 | — | 150,000 | |
| Stock-based compensation | — | — | — | — | 33,086 | — | 33,086 | |
| Net loss | — | — | — | — | — | (1,576,558) | (1,576,558) | |
| Balance at June 30, 2024 | — | $ | - | 192,278 | $47,514 | $116,086,316 | $(120,411,693) | $(4,277,863) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.